Erbitux and Cardiac failure congestive - a phase IV clinical study of FDA data

Summary:

Cardiac failure congestive is reported as a side effect among people who take Erbitux (cetuximab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Carboplatin, and have Oral cancer.

The phase IV clinical study analyzes which people have Cardiac failure congestive when taking Erbitux. It is created by eHealthMe based on reports of 19,227 people who have side effects when taking Erbitux from the FDA, and is updated regularly.

What is Erbitux?

Erbitux has active ingredients of cetuximab. It is often used in cancer. eHealthMe is studying from 19,276 Erbitux users. Check the latest studies of Erbitux.

What is Cardiac failure congestive?

Cardiac failure congestive is found to be associated with 2,154 drugs and 2,144 conditions by eHealthMe. Check the latest studies of Cardiac failure congestive.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 21, 2026

19,227 people reported to have side effects when taking Erbitux.
Among them, 25 people (0.13%) have Cardiac failure congestive.

Could Erbitux cause Cardiac failure congestive?

Among these 25 people:

How long have people been on Erbitux when they have Cardiac failure congestive? *

What is the gender of people who have Cardiac failure congestive when taking Erbitux? *

female: 43.48 %
male: 56.52 %

What is the age of people who have Cardiac failure congestive when taking Erbitux? *

What are other drugs people take besides Erbitux? *

What are other side effects people have besides Cardiac failure congestive? *

Pneumonia: 5 people, 20.00%
Anaemia (lack of blood): 4 people, 16.00%
Diarrhea: 4 people, 16.00%
Dyspnea (difficult or laboured breathing): 3 people, 12.00%
Pulmonary Embolism (blockage of the main artery of the lung): 3 people, 12.00%
Hypotension (abnormally low blood pressure): 3 people, 12.00%
Dizziness: 3 people, 12.00%
Acute Myocardial Infarction (acute heart attack): 3 people, 12.00%
Weakness: 3 people, 12.00%
Tricuspid Valve Disease (disease of heart valve): 2 people, 8.00%

What are the existing conditions these people have? *

Oral Cancer (mouth cancer): 4 people, 16.00%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 3 people, 12.00%
Diabetes: 3 people, 12.00%
High Blood Pressure: 3 people, 12.00%
Breast Cancer Metastatic: 2 people, 8.00%
Pain: 2 people, 8.00%
Multiple Myeloma (cancer of the plasma cells): 2 people, 8.00%
Metastatic Neoplasm (spreadable cancer tumour): 2 people, 8.00%
High Blood Cholesterol: 2 people, 8.00%
Squamous Cell Carcinoma (a cancer of a kind of epithelial cell): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Erbitux and have Cardiac failure congestive?

- Check whether Cardiac failure congestive is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Erbitux:

Erbitux (19,276 reports)

Browse all side effects of Erbitux:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cardiac failure congestive:

Cardiac failure congestive (2,154 drugs)

Browse all the conditions that are associated with Cardiac failure congestive:

Cardiac failure congestive (2,144 conditions)

Related publications that referenced our studies

Gupta D, Shukla P, Bisht SS, Bhatt ML, Pant MC, Srivastava K, "Deep vein and artery thrombosis associated with cetuximab-based chemoradiotherapy", Indian journal of pharmacology, 2011 Jan .
Gupta D, Shukla P, Bisht SS, Bhatt ML, Pant MC, Srivastava K, "Deep vein and artery thrombosis associated with cetuximab-based chemoradiotherapy", Indian journal of pharmacology, 2011 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cetuximab (the active ingredients of Erbitux) and Erbitux (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.